Spero Therapeutics (NASDAQ:SPRO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at
Wall Street
Spero Therapeutics (NASDAQ:SPRO) was downgraded by analysts at
Wall Stre
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis [Yahoo! Finance]
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis